Search

everythinglearnresearchcommunity

for

Search:↓

New tools help assess eyebrow, eyelash, and nail changes in Alopecia Areata, improving understanding of patient experiences.

A comprehensive scoring system for alopecia areata severity is needed.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

Patients and clinicians generally agree on eyebrow and eyelash hair loss improvements in severe alopecia areata.

The HAIR-Q is a reliable tool for assessing patient satisfaction with hair loss treatments.

Choosing the right recall period for patient feedback is important for accurate data and depends on the disease, symptom changes, and patient impact.

High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.

Baricitinib is effective and safe for treating severe alopecia areata.

Significant, lasting hair regrowth is needed to improve how patients with Alopecia Areata feel about their condition.

The Hair Check tool can measure hair loss, but patients' own reports are more reliable for assessing hair loss during chemotherapy.

Gender-affirming hormone treatments need better patient-focused outcome measurements and standardized data collection.

The instruments are valid but don't fully capture the emotional impact on adolescents with alopecia areata.

Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.

New tools were created to help lupus patients report their symptoms and impacts more accurately.

The new measure helps understand the personal and emotional impact of hair loss in alopecia areata patients.

The electronic version of the Dermatology Life Quality Index is as effective as the paper version, with most patients preferring it.

A new tool helps lupus patients and doctors better track symptoms and quality of life.

The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.

Disease-specific tools better assess alopecia areata's impact on quality of life.

Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

PRP injections improve voice quality and are safe for treating vocal fold scars.

Some treatments like intralesional steroids and 5α-reductase inhibitors are effective for frontal fibrosing alopecia, but more research is needed.

Injectable treatments like PRP can improve hair growth in women, but their effect on body image is unclear.

No current patient-reported outcome measure fully meets FDA requirements for alopecia treatments.

Skin disease activity scores can help decide when skin symptoms no longer affect the quality of life in patients with mild dermatomyositis.

Topical minoxidil is dangerous for cats and dogs.

Baseline severity and relapse history affect alopecia areata treatment and recurrence.

Patient-reported hair improvements align with actual hair density changes, not hair width.

The cream effectively treats scalp psoriasis, improving symptoms and quality of life, with high patient satisfaction.